Helix BioPharma Corp., a clinical-stage oncology company, announced the voting results from its Annual General and Special Meeting held on January 30, 2026. Shareholders voted overwhelmingly in favor of all items of business, including the re-election of four director nominees, the appointment of Clearhouse LLP as auditor, and a resolution to amend the company's articles to effect a share consolidation. A total of 61,885,815 common shares were voted, representing 81.03% of Helix's total issued and outstanding shares.
The four director nominees—Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube—were re-elected with 99.99% of votes cast in favor for each. The resolution to appoint Clearhouse LLP as auditor was also approved with 99.99% support. Additionally, shareholders authorized the board to consolidate the company's issued and outstanding common shares at a ratio of up to five pre-consolidation shares for one post-consolidation share, with the final ratio to be determined by the board. This consolidation is intended to potentially enhance the company's financial flexibility and attract institutional investors.
The strong shareholder approval underscores confidence in Helix BioPharma's strategic direction, particularly its focus on developing novel therapies for hard-to-treat cancers. The company's lead candidate, Tumour Defence Breaker L-DOS47, is an antibody-enzyme conjugate targeting CEACAM6-expressing solid tumors, including non-small cell lung cancer. Helix continues to advance its pipeline, with bispecific ADCs in discovery stages. The company is listed on the TSX under the symbol "HBP", on OTC PINK under "HBPCF", and on the Frankfurt Stock Exchange under "HBP0". Details of the meeting results will be filed on SEDAR+ at www.sedarplus.com.
Forward-looking statements in the announcement involve risks and uncertainties, including those related to financing, clinical trials, regulatory approvals, and strategic partnerships. These are more fully described in Helix's management discussion and analysis and annual information form, available on SEDAR+. The company does not assume any obligation to update forward-looking statements except as required by law.
